国内外同步发力，经营业绩继续保持快速增长

Investment Rating - The report maintains a "Recommendation" rating for the company, indicating an expected stock performance that will outperform the market by 10% to 20% within the next six months [5][24][28]. Core Viewpoints - The company has demonstrated rapid growth in operating performance, with a 37.09% year-on-year increase in revenue for 2023, reaching 509 million yuan, and a 49.86% increase in net profit, totaling 217 million yuan [8][9]. - The company continues to expand its domestic and international market presence, achieving significant revenue growth in both sectors, with domestic revenue reaching 261 million yuan and overseas revenue at 245 million yuan in 2023 [9][10]. - The company is focused on product innovation and R&D, with a 31.13% increase in R&D investment in 2023, amounting to 41.25 million yuan, and a further 64.47% increase in Q1 2024 [12][22]. - The company has established a strong product portfolio in the digestive consumables sector, with a stable product structure and significant growth in various product categories [22][24]. Financial Summary - The company reported a gross margin of 70.87% in 2023, with a further increase to 71.78% in Q1 2024, indicating strong profitability [22]. - The projected earnings per share (EPS) for 2024, 2025, and 2026 are 4.61 yuan, 5.92 yuan, and 7.72 yuan respectively, reflecting a positive growth outlook [10][24]. - The company's total assets are projected to grow from 2.33 billion yuan in 2023 to 3.43 billion yuan by 2026, demonstrating robust asset growth [14].